FOLH1 and pachyonychia congenita: Finally, the phase 1/2 NEPI trial will investigate neoadjuvant treatment with the radionuclide lutetium-177 vipivotide tetraxetan prostate-specific membrane antigen +/− ipilimumab in patients with very-high-risk PC (International Society of Urological Pathology-Gleason Grade 4 + 5 and cT3 plus cN+ or PSA > 20 ng/mL) who are candidates for RP [164].